HASTINGS DAVID C 4
4 · Trevi Therapeutics, Inc. · Filed Jan 12, 2026
Insider Transaction Report
Form 4
HASTINGS DAVID C
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
[F1]2026-01-08+375,000→ 375,000 totalExercise: $11.21Exp: 2036-01-07→ Common Stock (375,000 underlying)
Footnotes (1)
- [F1]This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.
Signature
/s/ Christopher Galletta, attorney-in-fact|2026-01-12